Related Experiment Videos
Pimagedine: a novel therapy for diabetic nephropathy
Emaad Abdel-Rahman1, W Kline Bolton
1Division of Nephrology, University of Virginia, Charlottesville 22908-0133, USA. ea6n@virginia.edu
Expert Opinion on Investigational Drugs
|April 2, 2002
Summary
Advanced glycation end products (AGEs) contribute to diabetic nephropathy. Pimagedine, an AGE inhibitor, shows promise in reducing diabetic kidney disease severity and may aid in its management.
Area of Science:
- Nephrology
- Endocrinology
- Biochemistry
Background:
- Hyperglycaemia (high blood sugar) drives long-term diabetic complications.
- Non-enzymatic protein glycation forms advanced glycation end products (AGEs), contributing to diabetic nephropathy.
- Diabetic nephropathy is a growing concern, leading to end-stage renal disease and the need for renal replacement therapy.
Purpose of the Study:
- To evaluate the potential of pimagedine (aminoguanidine HCl) in managing diabetic nephropathy.
- To explore the role of advanced glycation end products (AGEs) inhibitors in diabetic kidney disease.
Main Methods:
- Review of experimental studies on pimagedine's effects on diabetic nephropathy.
- Analysis of preliminary clinical data regarding pimagedine treatment in patients with diabetic nephropathy.
Main Results:
- Pimagedine effectively reduced structural and functional damage in experimental diabetic nephropathy.
- Preliminary studies indicate a beneficial effect of pimagedine in human diabetic nephropathy patients.
Conclusions:
- Advanced glycation end products (AGEs) play a significant role in diabetic nephropathy development.
- AGE inhibitors, such as pimagedine, show potential for managing diabetic nephropathy, possibly in combination with other treatments.